Goldman Sachs Adjusts Price Target on Bristol-Myers Squibb to $57 From $51, Maintains Neutral Rating

Goldman Sachs Adjusts Price Target on Bristol-Myers Squibb to $57 From $51, Maintains Neutral Rating — alphai